Mercer Global Advisors Inc. ADV lifted its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 4.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 123,689 shares of the company's stock after acquiring an additional 5,532 shares during the period. Mercer Global Advisors Inc. ADV's holdings in Sanofi were worth $5,966,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its position in shares of Sanofi by 1,210.4% during the 4th quarter. Jane Street Group LLC now owns 69,475 shares of the company's stock worth $3,351,000 after buying an additional 64,173 shares during the last quarter. Guardian Capital LP lifted its position in Sanofi by 1.2% in the fourth quarter. Guardian Capital LP now owns 113,296 shares of the company's stock valued at $5,464,000 after acquiring an additional 1,327 shares during the last quarter. Regal Partners Ltd acquired a new position in Sanofi in the fourth quarter valued at $35,034,000. Northern Trust Corp grew its holdings in shares of Sanofi by 44.9% during the fourth quarter. Northern Trust Corp now owns 1,930,560 shares of the company's stock worth $93,111,000 after purchasing an additional 597,959 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Sanofi by 122.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 356,058 shares of the company's stock worth $17,180,000 after purchasing an additional 195,719 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently issued reports on SNY. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, BNP Paribas assumed coverage on Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $63.33.
Get Our Latest Analysis on Sanofi
Sanofi Stock Performance
NASDAQ SNY traded down $2.15 during trading hours on Friday, hitting $49.98. 2,156,827 shares of the stock were exchanged, compared to its average volume of 2,370,259. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12. The stock has a 50-day moving average of $54.22 and a 200 day moving average of $52.00. The company has a market cap of $126.26 billion, a price-to-earnings ratio of 20.07, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same period last year, the firm earned $1.78 EPS. The company's quarterly revenue was down 11.0% compared to the same quarter last year. As a group, equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.
Sanofi Increases Dividend
The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a dividend of $2.0369 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is currently 57.14%.
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
